Citations (29)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (4)
Guanmin Chen, Behnam Sharif, Brittany Gerber, Megan S. Farris, Tara Cowling, Czerysh Cabalteja, Jennifer W. Wu, Bridget Maturi & Kristoph Klein-Panneton. (2021) Epidemiology, healthcare resource utilization and healthcare costs for spinal muscular atrophy in Alberta, Canada. Journal of Medical Economics 24:sup1, pages 51-59.
Read now
Read now
Cathleen Collins, Julie J. Kim-Chang, Elena Hsieh, Abigail Silber, Matthew O’Hara, Sarah Kulke & Megan A. Cooper. (2021) Economic burden of congenital athymia in the United States for patients receiving supportive care during the first 3 years of life. Journal of Medical Economics 24:1, pages 962-971.
Read now
Read now
Maria Stefanova Kamusheva & Maria Jordanova Dimitrova. (2020) Clinical and economic assessment of nusinersen: the Bulgarian perspective. Expert Opinion on Orphan Drugs 8:10, pages 403-415.
Read now
Read now
Lisa Belter, Rosángel Cruz, Sierra Kulas, Emily McGinnis, Omar Dabbous & Jill Jarecki. (2020) Economic burden of spinal muscular atrophy: an analysis of claims data. Journal of Market Access & Health Policy 8:1.
Read now
Read now
Articles from other publishers (25)
I. A. Komarov, A. R. Malakhova, T. P. Vasilyeva, E. Yu. Shukan, O. Yu. Aleksandrova, R. A. Zinchenko, A. V. Polyakov, S. S. Nikitin, E. Yu. Sapego & S. I. Kutsev. (2023) Socioeconomic efficiency of neonatal screening for spinal muscular atrophy in the Russian Federation. Neuromuscular Diseases 13:3, pages 25-32.
Crossref
Crossref
Walter Toro, Min Yang, Mihaela Georgieva, Wei Song, Anish Patel, Anya Jiang, Angela Zhao, Nicole LaMarca & Omar Dabbous. (2023) Health Care Resource Utilization and Costs for Patients with Spinal Muscular Atrophy: Findings from a Retrospective US Claims Database Analysis. Advances in Therapy 40:10, pages 4589-4605.
Crossref
Crossref
Damian May, Kalé Kponee-Shovein, Malena Mahendran, Nathaniel Downes, Kristy Sheng, Patrick Lefebvre & Wendy Y. Cheng. (2023) Epidemiology and patient journey of Rett syndrome in the United States: a real-world evidence study. BMC Neurology 23:1.
Crossref
Crossref
Arian Khorshid, Alleigh L. H. Boyd, Barry Behr, Qianying Zhao, Ruben Alvero & Brindha Bavan. (2023) Cost-effectiveness of IVF with PGT-M/A to prevent transmission of spinal muscular atrophy in offspring of carrier couples. Journal of Assisted Reproduction and Genetics 40:4, pages 793-801.
Crossref
Crossref
David Fox, Tu My To, Arpamas Seetasith, Anisha M. Patel & Susan T. Iannaccone. (2022) Adherence and Persistence to Nusinersen for Spinal Muscular Atrophy: A US Claims-Based Analysis. Advances in Therapy 40:3, pages 903-919.
Crossref
Crossref
Nikoletta M. Margaretos, Komal Bawa, Natalie J. Engmann & James D. Chambers. (2022) Patients’ access to rare neuromuscular disease therapies varies across US private insurers. Orphanet Journal of Rare Diseases 17:1.
Crossref
Crossref
Sophelia H. S. Chan, Carlos K. H. Wong, Tingting Wu, Wilfred Wong, Michael K. L. Yu, Ivan C. H. Au & Godfrey C. F. Chan. (2022) Significant healthcare burden and life cost of spinal muscular atrophy: real-world data. The European Journal of Health Economics.
Crossref
Crossref
Min Yang, Hiroyuki Awano, Satoru Tanaka, Walter Toro, Su Zhang, Omar Dabbous & Ataru Igarashi. (2022) Systematic Literature Review of Clinical and Economic Evidence for Spinal Muscular Atrophy. Advances in Therapy 39:5, pages 1915-1958.
Crossref
Crossref
Noman Paracha, Pollyanna Hudson, Stephen Mitchell & C. Simone Sutherland. (2021) Systematic Literature Review to Assess the Cost and Resource Use Associated with Spinal Muscular Atrophy Management. PharmacoEconomics 40:S1, pages 11-38.
Crossref
Crossref
Aleksei S. Kolbin, Dmitriy V. Vlodavets, Aleksei A. Kurylev, Olga Yu. Germanenko & Natalia Yu. Kolbina. (2021) Health Technologies Assessment for Orphan Diseases. Example of Social and Economic Burden of Spinal Muscular Atrophy. Pediatric pharmacology 18:5, pages 408-415.
Crossref
Crossref
Katharina Vill, Oliver Schwartz, Astrid Blaschek, Dieter Gläser, Uta Nennstiel, Brunhilde Wirth, Siegfried Burggraf, Wulf Röschinger, Marc Becker, Ludwig Czibere, Jürgen Durner, Katja Eggermann, Bernhard Olgemöller, Erik Harms, Ulrike Schara, Heike Kölbel & Wolfgang Müller-Felber. (2021) Newborn screening for spinal muscular atrophy in Germany: clinical results after 2 years. Orphanet Journal of Rare Diseases 16:1.
Crossref
Crossref
Tamara Dangouloff, Camille Botty, Charlotte Beaudart, Laurent Servais & Mickaël Hiligsmann. (2021) Systematic literature review of the economic burden of spinal muscular atrophy and economic evaluations of treatments. Orphanet Journal of Rare Diseases 16:1.
Crossref
Crossref
Alisha Monnette, Er Chen, Dongzhe Hong, Alessandra Bazzano, Stacy Dixon, W. David Arnold & Lizheng Shi. (2021) Treatment preference among patients with spinal muscular atrophy (SMA): a discrete choice experiment. Orphanet Journal of Rare Diseases 16:1.
Crossref
Crossref
Marjolaine Gauthier-Loiselle, Martin Cloutier, Walter Toro, Anish Patel, Sherry Shi, Mikhail Davidson, Matthias Bischof, Nicole LaMarca & Omar Dabbous. (2021) Nusinersen for Spinal Muscular Atrophy in the United States: Findings From a Retrospective Claims Database Analysis. Advances in Therapy 38:12, pages 5809-5828.
Crossref
Crossref
Nicole B. Johnson, Crystal Proud, Christina L. Wassel, Jill Dreyfus, Thos Cochrane & Angela D. Paradis. (2021) Characterization of Adult Patients With SMA Treated in US Hospital Settings: A Natural History Study in the Premier Healthcare Database. Journal of Neuromuscular Diseases 8:4, pages 569-578.
Crossref
Crossref
Maggie C. Walter, Claudia Chiriboga, Tina Duong, Nathalie Goemans, Anna Mayhew, Laëtitia Ouillade, Maryam Oskoui, Ros Quinlivan, Juan F. Vázquez-Costa, John Vissing & Laurent Servais. (2021) Improving Care and Empowering Adults Living with SMA: A Call to Action in the New Treatment Era. Journal of Neuromuscular Diseases 8:4, pages 543-551.
Crossref
Crossref
H.J. McMillan, B. Gerber, T. Cowling, W. Khuu, M. Mayer, J.W. Wu, B. Maturi, K. Klein-Panneton, C. Cabalteja & H. Lochmüller. (2021) Burden of Spinal Muscular Atrophy (SMA) on Patients and Caregivers in Canada. Journal of Neuromuscular Diseases 8:4, pages 553-568.
Crossref
Crossref
Meaghann S. Weaver, Alice Yuroff, Sarah Sund, Scott Hetzel & Matthew A. Halanski. (2021) Quality of Life Outcomes According to Differential Nusinersen Exposure in Pediatric Spinal Muscular Atrophy. Children 8:7, pages 604.
Crossref
Crossref
Erik Landfeldt, Astrid Pechmann, Hugh J. McMillan, Hanns Lochmüller & Thomas Sejersen. (2021) Costs of Illness of Spinal Muscular Atrophy: A Systematic Review. Applied Health Economics and Health Policy 19:4, pages 501-520.
Crossref
Crossref
Katherine D. Mathews & Susan T. Iannaccone. (2020) Combination molecular therapies for spinal muscular atrophy: How much is enough?. Muscle & Nerve 63:3, pages 279-281.
Crossref
Crossref
A. S. Kolbin, D. V. Vlodavets, A. A. Kurylev, Yu. Ye. Balykina, M. A. Proskurin, S. A. Mishinova, O. Yu. Germanenko & N. Yu. Kolbina. (2021) The social-economic burden of spinal muscular atrophy in Russia. FARMAKOEKONOMIKA. Modern Pharmacoeconomic and Pharmacoepidemiology 13:4, pages 337-354.
Crossref
Crossref
Isaac Aranda-Reneo, Luz María Peña-Longobardo, Juan Oliva-Moreno, Svenja Litzkendorf, Isabelle Durand-Zaleski, Eduardo F. Tizzano & Julio López-Bastida. (2020) The Burden of Spinal Muscular Atrophy on Informal Caregivers. International Journal of Environmental Research and Public Health 17:23, pages 8989.
Crossref
Crossref
Lisa Belter, Rosángel Cruz & Jill Jarecki. (2020) Quality of life data for individuals affected by spinal muscular atrophy: a baseline dataset from the Cure SMA Community Update Survey. Orphanet Journal of Rare Diseases 15:1.
Crossref
Crossref
Georgina M. Chambers, Stella Nalukwago SettumbaKate A. CareyAnita CairnsManoj P. MenezesMonique RyanMichelle A. Farrar. (2020) Prenusinersen economic and health-related quality of life burden of spinal muscular atrophy. Neurology 95:1.
Crossref
Crossref
Mark Rafisovich Shaymurzin. (2019) STRATEGY OF DIFFERENTIATED MULTI-STAGE THERAPY OF PROXIMAL SPINAL AMIOTROPHY IN CHILDREN. AVICENNA BULLETIN 21:3, pages 408-414.
Crossref
Crossref